CRISPR Eradicates Latent HIV-1, Offering Hope of "Functional Cures"

Scientists in Japan have used CRISPR-Cas9 technology to stop human immunodeficiency virus type 1 (HIV-1) replication in latently infected T cells that can’t be controlled using existing drug treatments. The gene-editing approach effectively disrupts two regulatory HIV-1 genes, tat and rev , which are essential for viral replication. Describing their in vitro studies in Scientific Reports , the researchers at Kobe University Graduate School of Medicine and Kobe University Graduate School of